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COVID-19 pandemic mitigation strategies are mainly based on social distancing measures and healthcare system 
reinforcement. However, many countries in Europe and elsewhere implemented strict, horizontal lockdowns 
because of extensive viral spread in the community which challenges the capacity of the healthcare systems. 
However, strict lockdowns have various untintended adverse social, economic and health effects, which have yet 
to be fully elucidated, and have not been considered in models examining the effects of various mitigation 
measures. Unlike commonly suggested, the dilemma is not about health vs wealth because the economic 
devastation of long-lasting lockdowns will definitely have adverse health effects in the population. Furthermore, 
they cannot provide a lasting solution in pandemic containment, potentially resulting in a vicious cycle of 
consecutive lockdowns with in-between breaks. Hospital preparedness has been the main strategy used by 
governments. However, a major characteristic of the COVID-19 pandemic is the rapid viral transmission in 
populations with no immunity. Thus, even the best hospital system could not cope with the demand. Primary, 
community and home care are the only viable strategies that could achieve the goal of pandemic mitigation. We 
present the case example of Greece, a country which followed a strategy focused on hospital preparedness but 
failed to reinforce primary and community care. This, along with strategic mistakes in epidemiological sur-
veillance, resulted in Greece implementing a second strict, horizontal lockdown and having one of the highest 
COVID-19 death rates in Europe during the second wave. We provide recommendations for measures that will 
reinstate primary and community care at the forefront in managing the current public health crisis by protecting 
hospitals from unnecessary admissions, providing primary and secondary prevention services in relation to 
COVID-19 and maintaining population health through treatment of non− COVID-19 conditions. This, together 
with more selective social distancing measures (instead of horizontal lockdowns), represents the only viable and 
realistic long-term strategy for COVID-19 pandemic mitigation.   
1. Introduction 
As the world continues to navigate through the uncertainties of 
COVID-19, it becomes evident that the dynamic of the pandemic can 
easily overwhelm healthcare systems globally and impose serious 
adverse health, economic and social effects on the population. Even in 
Western, high-resource regions, such as Northern Italy or New York, 
hospitals and intensive care units (ICU) were under extreme pressure 
during the first pandemic wave in spring of 2020, resulting in difficult 
prioritization decisions about treatment based on factors such as age, 
comorbidities and functional status [1–3]. The risk of exceeding 
healthcare systems capacity has led to social (physical) distancing 
measures, which frequently mandate strict, horizontal lockdowns with 
universal restriction of movement affecting the whole population. 
While using extreme lockdowns as the main strategy at the beginning 
of the pandemic was expected and defendable, considering the lack of 
preparedness in dealing with a public health crisis and the uncertainty 
over the case fatality rate, the second and third waves that are currently 
in full force throughout Europe and the US, respectively, have proven 
that lockdowns are not a measure with long-term and sustained miti-
gation effects, let alone a viable and definite solution. Instead, they 
could be used only as temporary measures to “buy time” and reorganize 
the healthcare and public health response, develop resources to effec-
tively detect, isolate, test and care for all cases, as well as introduce other 
non-pharmacotherapeutic interventions and empower the population to 
develop an appropriate societal response, or even initiate plans for long- 
term pandemic prevention [4–7]. Lockdowns have been shown to 
reduce the effective reproduction number (R), i.e., the number of people 
infected by each infected person at short term [8]. However, strict 
lockdowns that include social distancing for the whole population, 
including younger people, might only confer temporary benefits and 
could result in more deaths long-term because the pandemic is pro-
longed and COVID-19 related mortality is highly skewed towards older 
age groups [9]. Therefore, intense and horizontal social distancing in-
terventions may end-up causing more harm than good in terms of 
COVID-19 mortality, despite the best of intentions. But more impor-
tantly, all models analyzing the impact of lockdown on SARS-CoV-2 
transmission and COVID-19 mortality fail to consider the potentially 
devastating adverse effects on other diseases. They also fail to consider 
the adverse economic and social consequences that can cause medium 
and long-term health harm on the whole population, particularly the 
younger and most productive population subgroups. This omission is in 
direct conflict with fundamental public health principles that dictate all 
decisions should be based on a holistic and careful assessment and 
weighing of intended benefits and unintended harms. Unintended 
adverse effects of lockdowns have already been observed. In Italy, the 
fatality rate in patients with myocardial infarction who presented to 
hospitals was increased by 3-fold with a parallel almost 2-fold higher 
risk for complications between March 12–19, 2020, during the period of 
lockdown, compared to the same week of 2019 [10]. Reduced rates of 
hospital admission for acute coronary syndrome were also observed, 
most likely due to patients’ fear of being exposed to an environment 
with high risk of SARS-CoV-2 infection as well as delayed treatment 
[10–14]. In England and Wales, acute cardiovascular deaths at home 
were increased by 35 % compared to 2014–2019 [15]. Most of these 
deaths were not related to SARS-CoV-2 infection [15]. Besides the im-
mediate effects on mortality, these issues are expected to have 
long-lasting, perhaps life-long, implications in patients who will end up 
with heart failure, leading to a reduction in life expectancy and a 
potentially dramatic decline in quality of life. Excess mortality has been 
observed in several countries, which is not solely attributed to COVID-19 
[16,17]. Primary prevention strategies are expected to be disrupted. In 
the UK, approximately 1 million mammograms have been skipped, 
resulting in an estimated 8600 women who could be living with unde-
tected breast cancer because of their diagnosis being delayed [18]. Other 
primary prevention programs are also expected to be impacted by the 
pandemic. The mental health impact of extreme social restrictions is also 
expected to be devastating, considering the impact observed in prior 
pandemics [19]. Mental disorders are associated with more than 2-fold 
higher relative risk for all-cause mortality, with the median years of 
potential life lost being 10 years [20]. In Switzerland, it was projected 
that approximately 180,000 people (2.1 % of the population) will be 
affected and 1.7 million life years may be lost as a result of lockdowns, 
due to mental health factors such as suicide, divorces, family violence, 
depression, and alcohol use disorder [21]. An important portion of the 
damage caused by stress-related issues may be hard or impossible to 
reverse, resulting in sustained suffering that is expected to last much 
longer than the physical health impact of the pandemic [21]. Children 
and adolescents are not expected to be spared from the adverse effects, 
and the disruption in education and socialization through school in-
teractions is expected to cause even more problems [22,23]. Substance 
abuse is also increased during the stressful period of lockdowns, often 
stimulated by aggressive misleading “infosaturation” or “infoxication” 
regarding its supposed therapeutic benefits. [24,25]. Last but not least, 
the socioeconomic effects are expected to result in rising unemployment, 
poverty, and exacerbation of social and health inequalities that may be 
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long-lasting [26,27]. It should be mentioned that not all population 
subgroups carry the same risk for severe COVID-19 and death. Unlike 
the 1918 Spanish flu pandemic in which peak mortality was observed at 
the age of 28 [28], COVID-19-associated mortality is mainly affecting 
the elderly and people with comorbidities [29,30]. Specifically, epide-
miological data suggest that factors such as obesity, cardiovascular risk 
factors and established vascular disease are associated with elevated risk 
for severe COVID-19, with microvascular thrombosis in the lungs and 
other systems being the main pathophysiological features [31]. At the 
same time, immune dysfunction, perhaps linked with environmental 
factors, toxin exposure as well as comorbidities seems to be a major 
determinant of severe COVID-19 severity. Besides people with comor-
bidities, socially disadvantaged groups have been shown to be dispro-
portionately affected by COVID-19 [32–35]. These features led to the 
characterization of the COVID-19 global threat as a syndemic, instead of 
a pandemic, a synergistic interaction of an infectious disease with an 
array of non-communicable diseases as well as socioeconomic factors 
[36]. Therefore, measures such as strict lockdowns have the potential to 
create another potential form of “inequality” between population sub-
groups in terms of expected benefits and potential harms from public 
health measures and interventions relevant to COVID-19 mitigation. 
Even children are part of this “inequality”. School closures, which are 
known to be associated with multiple harms [37], are not implemented 
in order to protect the health of children from SARS-CoV-2 infection 
(which is almost universally mild) but in order to reduce viral trans-
mission to vulnerable groups. All these adverse effects are not neces-
sarily acute and easily detectable but may evolve over time and may be 
long-lasting. For example, unemployment is associated with a 63 % 
higher mortality risk, adjusted for age and other covariates, and affects 
mainly those in their early and middle careers, which translates to 
younger age groups [38]. Furthermore, it should be emphasized that the 
decisions to implement strict, horizontal lockdowns are not a trade-off 
between health and wealth, with the interest of public health being 
favored over economic benefit. In fact, this represents a pseudo-dilemma 
since economic deprivation is closely and directly linked to public and 
population health deterioration. 
While there is definitely the need to protect the vulnerable, careful 
planning and modelling are necessary so that the net positive outcomes 
of each intervention far outweigh the negative effects on a population 
level, not only in the short term but also in the long term. This has been 
largely ignored during this pandemic while it should have been at the 
forefront of the decision-making framework, with consideration for 
alternative interventions or effective strategies to mitigate their adverse 
impact [39,40]. Finally, while some concerns have been raised about 
human rights and democracy due to the measures of restricting move-
ment, preventing people from working and socializing and other rele-
vant government decisions [41], this is acceptable during public health 
crises. Still, it is important that such measures are of limited duration, 
based on scientific evidence, lawful, necessary, proportionate, 
non-discriminatory and least intrusive and restrictive possible in order 
to reach the objective [42]. At the same time, freedom of expression and 
access to critical information need to be protected [42]. 
All the above generate serious concerns about the use of horizontal 
lockdowns as the central and dominant measure to control and mitigate 
the impact of COVID-19 incidence, morbidity and mortality. In fact, we 
may have only recorded and witnessed “the tip of the iceberg” in terms 
of unintended harms of extreme lockdowns and other approaches in 
mitigating the pandemic, with the full extent and magnitude of adverse 
effects not yet being fully developed. Furthermore, lockdowns have been 
proven to have temporary effects only, since a second pandemic wave 
has occurred throughout Europe, while the benefit of horizontal, strict 
lockdowns, compared to partial lockdowns or curfew only, in preventing 
deaths remains unclear [43]. We are already seeing signs that this 
strategy could result in a vicious cycle of consecutive strict lockdowns, 
with short in-between breaks, especially during the winter when 
weather conditions facilitate viral spread. There is no doubt that social 
distancing measures and restrictions of movement are necessary as part 
of a mitigation strategy. Horizontal lockdowns for the whole population 
may be essential as a measure of last resort, either due to too many 
unknowns or out of despair because of uncontrollable viral spread and 
overwhelmed healthcare systems. However, considering the potentially 
harmful effects of such lockdowns, a more sustainable and realistic 
strategy is needed to effectively and holistically combat the pandemic. 
Additionally, a longer-term strategy to reduce morbidity and mortality 
from this and future pandemics is needed, focusing on environmental 
factors, toxin exposure and other risk factors for non-communicable 
diseases that potentially compromise the function of the immune sys-
tem and increase infectious disease susceptibility and severity. 
2. Hospital preparedness 
Hospital preparedness is critical in organizing the national and local 
response to communicable disease epidemics. Increasing bed capacity, 
adjusting the infrastructure and re-allocating human and equipment 
resources, implementation of measures to protect staff, patients and 
visitors and training of personnel are important measures in dealing 
with a communicable disease crisis [44]. Such measures were the focus 
of interventions during the initial stages of the COVID-19 pandemic. On 
a European level, governments have been mobilizing special funds and 
used private donations to increase workforce capacity and to obtain 
additional equipment, including personal protective equipment and 
ventilators [45]. However, it soon became apparent that hospitals can 
easily be overwhelmed. In countries such as Spain and Italy, hospitals 
rapidly reached 100 % occupancy, despite efforts to place additional 
beds in improvised ward areas and repurpose post-anesthesia and car-
diac care units into ICUs for COVID-19 cases [46–48]. This was expected 
since the virus is highly contagious and rapid transmission occurs in 
communities with no immunity to SARS-CoV-2. In fact, hospitals could 
become highly contaminated and thus become transformed into vectors 
of the disease, facilitating transmission to uninfected, vulnerable pa-
tients [47]. Hospital staff becomes exhausted, resulting in compromise 
of quality of care. Additionally, the elevated risk of being infected with a 
high viral load, which can even increase the risk of severe COVID-19 and 
death, may result in a further reduction of hospital capacity due to loss 
of personnel [49]. As expected, front-line healthcare workers are by far 
more likely to be infected with SARS-CoV-2 compared to the general 
population even when adjusting for the frequency of being tested. This 
can have significant implications in viral transmission to high-risk in-
dividuals seeking care for other health conditions [50]. Therefore, even 
if substantial financial and other resources were dedicated to hospital 
preparedness, it would still be inadequate to contain and mitigate the 
effects of the pandemic if no other measures are taken. Last but not least, 
national policies and national preparedness, both for organizing hospital 
services and for non-pharmacological intervention strategies, are 
needed so that the public health response is organized, the population 
receives consistent messages, and challenges such as resource capacity 
and local outbreaks are adequately addressed through cooperation and 
planning. At the same time, national policies should be flexible enough 
to accommodate for regional unique characteristics that would require 
policy adjustments. 
3. Primary health care, community and home care 
Fatality data were initially based on confirmed cases of SARS-CoV-2 
infection. The case fatality rate was estimated at 3.4 % according to a 
World health Organization (WHO) briefing in early March 2020 [51]. 
However, as for many infectious diseases, this represented a gross 
overestimation because a substantial proportion of infected people are 
undetected due to being asymptomatic or oligo-symptomatic and thus 
typically not seeking medical assistance [52]. Massive under-testing was 
also a serious problem, particularly at the beginning of the pandemic but 
also more recently [53,54]. Serological studies allowed the calculation 
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of infection fatality rate, which turned out to be much lower than the 
case fatality rate, particularly for people < 65 years old and no serious 
comorbidities [55–57]. Large differences in death risk were found be-
tween different age groups and comorbidities [58,59]. Additionally, 
patients with poorly-controlled comorbidities may have a further in-
crease in the risk for severe COVID-19 and death [58]. All the above 
indicate that a large proportion of COVID-19 patients will not need 
hospitalization, while, with appropriate interventions outside hospitals, 
and perhaps pharmacotherapies that are currently under investigation, 
the need to access secondary and tertiary healthcare services can be 
further reduced [60–63]. 
Primary healthcare and community care can have a central role in 
relieving the pressure from hospitals and maintaining population health. 
Previous data suggest that access to a family physician improves patient 
satisfaction, hospitalization rates, clinical outcomes and equity [64–66]. 
Therefore, primary care can essentially become the critical first line of 
defense through multiple primary and secondary prevention in-
terventions in relation to COVID-19. Community education and risk 
communication, risk stratification and identification of vulnerable 
groups that need to be more aggressively protected from infection, 
pharmaceutical control of comorbidities that are recognized risk factors 
for severe COVID-19 and interventions to reduce health inequalities can 
only be achieved through a coordinated and well-planned action of 
primary and community health care. The usually long-lasting and trus-
ted relationship between primary care physicians and patients ensures 
an open line of communication and may even prevent misinformation 
and misperceptions [67]. Differential diagnosis, testing and early 
detection of SARS-CoV-2 infection, contact tracing, supportive treat-
ment, triage and risk assessment at individual, family and community 
levels are important secondary prevention measures. Coordination, 
motivation and monitoring of case isolation is another priority that can 
be handled by family physicians [68]. Home monitoring and care are 
also crucial, not only to reduce hospital admissions but also to timely 
identify worsening disease that would lead to prompt referral for hos-
pitalized care before the development of irreversible health damage. For 
example, patients with vascular disease, who are at high risk for severe 
COVID-19, may need to be placed in close medical follow-up and 
assessed regularly by primary care physicians according to recom-
mended guidelines [69]. Home visits, telephone and online health 
consultation, and delivery of simple equipment such as oxygen therapy 
and pulse oximeters are the main responsibilities of primary and com-
munity care interventions [47]. Additional services, such as delivery of 
medical and food supplies and domestic support can be provided by 
establishing local community care teams composed of community 
nurses, health visitors and social workers. Organized phone centers, 
dedicated to individuals with suspected or confirmed COVID-19, could 
be established locally, that will provide guidance, coordinate the testing 
and contact tracing process, and provide consulting and support for 
ambulatory patients with COVID-19. After hospitalization for 
COVID-19, primary care is crucial for rehabilitation, management of 
post-acute COVID-19 and community follow-up [70]. These measures 
contribute not only to rapid recovery and improvement in quality of life 
but also to shortening hospital stay and thus increasing available hos-
pital resources. An additional pressing issue is the management of 
mental health problems that appear to be highly prevalent in patients 
recovering from COVID-19 [71,72]. Primary care is also responsible for 
maintaining the delivery of essential health services irrelevant to 
COVID-19, both in primary and secondary prevention, in order to reduce 
morbidity and mortality from other diseases. Finally, a key intervention 
in alleviating pressure to hospitals is to prioritize in the primary care 
setting conditions that could reduce non− COVID-19 related admissions 
to hospitals. It is well-established that a large proportion of hospital 
admissions are unplanned, i.e. non-elective, with a substantial propor-
tion being considered unnecessary as most of these patients could have 
been cared for in the community [73,74]. Several health conditions, 
called ambulatory care sensitive conditions, have been identified, with 
hospital admissions potentially being prevented through primary care 
interventions. While previous studies have identified the important role 
of ambulatory care sensitive conditions as markers of accessibility, 
effectiveness and quality of primary care [75–77], it now becomes 
crucial to develop an effective strategy of safely reducing unplanned 
admissions through targeted primary and community care activities and 
services. Prioritizing interventions for conditions such as influenza, 
chronic obstructive lung disease, congestive heart failure and urinary 
tract infections appear promising in freeing up hospital capacity to deal 
with COVID-19 patients [78]. The role of primary care is indispensable 
particularly for underprivileged individuals and people with limited or 
distant access to hospital care such as those living in rural areas, which 
probably represent high risk groups for severe COVID-19. 
It is now apparent that the battle against the pandemic cannot be 
won through a patient-centered care model driven by hospitals and 
intensive care [47]. Even the best hospital system would struggle to 
contain a pandemic of this scale. Instead, the key in managing this public 
health crisis is to reinforce but at the same time protect hospitals, by 
reducing the numbers of total and high-risk COVID-19 patients who will 
require hospitalized care. This can be a feasible goal. However, it needs a 
strong and coordinated effort by primary, community and home care so 
that it can be achieved safely and effectively, in addition to selective and 
carefully planned social distancing measures. An outline of the role of 
primary, community and home care in handling the pandemic is pre-
sented in Table 1. 
4. Healthcare preparedness and interventions in Greece: a case 
example 
The Greek national health system provides healthcare benefits/ser-
vices through a network of public/state providers and contracted private 
providers of primary, hospital and ambulatory care [79]. The National 
Organization for the Provision of Health Services (Greek acronym: 
EOPYY) was formed in recent years by merging four of the largest social 
security organizations, being responsible for negotiating contracts and 
remunerates health professionals. Primary healthcare is provided by 
EOPYY-contracted private-practice physicians, diagnostic centers and 
Table 1 
The role of primary, community and home care in COVID-19 pandemic 
mitigation.  
Primary prevention Education/information/risk communication campaigns  
Risk stratification  
Prioritize high-risk individuals  
Pharmaceutical control of comorbidities which are risk 
factors for COVID-19  
Reduce health inequalities  
Managing mental health effects 
Secondary Prevention Differential diagnosis between SARS-CoV-2 and other 
infections  
Testing and early identification of cases  
Contact tracing  
Supportive treatment - delivery of simple equipment  
Home care  
Triage  
Coordination/motivation/monitoring of case isolation  
Phone/online consultation and support  
Timely identification of worsening COVID-19 disease  
Managing mental health effects  
Domestic support, food and medication supplies for those in 
quarantine 
Post-COVID-19 Care Rehabilitation  
Management of post-acute COVID-19  
Community follow-up  
Management of mental health effects 
Managing other 
conditions 
Delivery of essential health services  
Vaccinations  
Treating patients with ambulatory care sensitive conditions  
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private clinics, public National Primary Healthcare Network (now 
transformed into health centers), and State hospitals, health centers, 
rural and regional medical units. Hospital care is provided by 
EOPYY-contracted private clinics and state hospitals. There are about 
3500 clinical and 2000 laboratory physicians who are contracted by 
EOPYY for providing health services, and about 800 family physicians 
(mostly general practitioners, internists and pediatricians). Character-
istically, there are many prefectures that do not have any pediatrician or 
general practitioner contracted by EOPYY. Moreover, there are thou-
sands of private doctors who provide services paid by the patients, but 
can also prescribe medications and diagnostic tests, with the cost being 
coveredςι (usually in part) by EOPYY. Private healthcare providers are 
prominent in primary care, especially in diagnostic technologies, private 
physicians’ practice and pharmaceuticals [79]. The system is financed 
by the state budget, social insurance contributions and private 
payments. 
The responsibility for developing a strategy for pandemic contain-
ment and mitigation and submit proposals for public health measures to 
the government was assigned to the National Public Health Organization 
(EODY). The initial response to the pandemic was mainly focused on 
enhancing hospital resources in terms of personal protective equipment, 
specialized care equipment such as ventilators, expansion of ICU beds 
and hiring healthcare personnel. Private donations also helped sup-
porting the increased needs of the healthcare system. These were 
necessary steps considering the budget cuts during the recent economic 
crisis, particularly in public health expenditure and management, pri-
mary healthcare and critical care [80,81]. Social distancing measures 
were soon implemented in the country. With the first confirmed 
COVID-19 case being diagnosed on February 26, 2020, all schools were 
closed. On March 13, one day after the first death from COVID-19 was 
recorded, cafes, bars, museums, shopping centers, sports facilities and 
restaurants were closed, followed by retail shops on March 16. Finally, 
on March 23, restrictions on all non-essential movement throughout the 
country were implemented, with signed attestation or mobile phone 
SMS notification required for all movement outside the home for specific 
reasons such as health reasons, buying essential goods, assisting other 
people in need and exercising [82]. Restrictions were gradually lifted 
starting from May 4, after a 42-day lockdown. Until that time, 2632 
confirmed cases and 146 deaths had been recorded. The beginning of the 
second wave of the pandemic occurred in August and increased still 
further after mid-October. The number of daily deaths started to rise in 
mid-September and further increased by early November to a 7-day 
moving average of 34 deaths per day (in November 11, 2020, from a 
maximum of 5 deaths per day in spring during the first wave of the 
pandemic). On that day, the second strict lockdown was announced, 
with schools retail, restaurants and nightlife closure, and with permis-
sion to leave home only for specific reasons (such as for work, health 
reasons, exercise, buying food supplies and to provide assistance to 
people in need) for which written attestation or mobile phone SMS 
notification was required (similarly to the first lockdown). 
While efforts were focused on hospital re-organization and rein-
forcement, primary and community care were largely neglected. Char-
acteristically, it was only on October 8, almost 7 months after the 
pandemic was declared by the WHO, that 160 health centers and 48 
rural medical units were announced to participate in the management of 
patients suspected of having COVID-19 [83]. Patients with symptoms 
compatible with COVID-19 would need to schedule an appointment, 
either by phone or electronically, in order to be examined and tested at 
no cost [84]. It is still is unclear if everyone could be tested on the same 
day of asking for an appointment, while asymptomatic close contacts 
were apparently not included in the criteria for testing. Thus, the rapid 
identification and diagnosis of suspected COVID-19 cases and their 
closed contacts was in all likelihood compromised. No clear plan was 
announced about the role and the actions of primary care health centers 
and family physicians in triage, treatment and home care for individuals 
not needing hospital admission. Additionally, the testing capacity of 
primary healthcare centers is probably inadequate to handle the 
increased demand. As a result, people who want or need to be tested for 
SARS-CoV-2, mainly those who are ambulatory and either asymptomatic 
or with mild symptoms, have no other alternative but to visit hospitals 
which are on duty for emergencies in order to perform a diagnostic test. 
This represents a crucial, strategic mistake. It adds to the pressure 
already applied to hospitals and represents a waste of personnel and 
resources which should be mainly dedicated to the care of patients with 
severe disease. In fact, in a desperate effort to increase hospitals 
personnel capacity, healthcare professionals are being transferred from 
health centers to hospitals, further weakening primary care [85]. These 
may be preliminary signs of the hospital care system being close to its 
limits, and it is unclear how this situation has compromised the care for 
patients with other diseases. At the same time, the contamination 
burden of hospitals is expected to increase, resulting in higher viral 
exposure of the personnel and of non-infected (but high-risk) patients. 
Transmission may also be facilitated among people queuing for diag-
nostic tests. Hospitals can easily become “microbubbles” and major 
vectors of disease. An additional problem was that, according to media 
reports, hospitals were apparently used as isolation facilities for 
oligo-symptomatic COVID-19 patients who could not follow quarantine, 
social distancing and personal hygiene measures, such as migrants and 
refugees, further wasting valuable hospital resources [86]. Finally, some 
specialized infectious disease hospitals which were shut down in pre-
vious years were not re-opened during the pandemic. This represents a 
missed opportunity to at least isolate COVID-19 patients from 
non-infected patients who are hospitalized in general hospitals for other 
diseases. 
No effort was made to reinforce the role of family physicians. There 
was no provision to provide them with personal protective and other 
equipment, or to accelerate the recruitment of more family physicians in 
an already-deficient system. Consequently, home care was largely 
neglected and unable to participate in the pandemic mitigation efforts. 
Private-practice physicians and diagnostic centers have been largely left 
out from the pandemic mitigation strategy. EOPYY does not compensate 
(neither fully nor in part) the diagnostic tests prescribed by private 
practice doctors. Even the large number of private laboratories which 
are contracted with EOPYY to provide services to patients (with the 
large part of the cost being compensated by EOPYY) do not receive any 
compensation for SARS-CoV-2 diagnostic tests. Therefore patients who 
make use of such diagnostic tests in private laboratories need to 
personally cover the whole cost. This represents a missed opportunity to 
increase testing capacity and alleviate the pressure from public hospitals 
and health centers which are overwhelmed by the current demand. 
Moreover, it results in delays in epidemiological surveillance, which 
should be based on the rapid identification and diagnosis of infected 
people and their close contacts so that isolation is implemented in a 
timely manner before transmitting the virus to other members of the 
community. Other efforts to increase testing capacity were mainly 
limited to initiatives by EODY, municipalities or peripheries to organize 
field testing for a limited number of days in major cities and towns. 
Anyone who wanted to be tested (irrespective of the presence or absence 
of symptoms) could perform a rapid antigen or a PCR test, even without 
physician prescription or recommendation. However, such initiatives 
lasted for a few days only, were not repeated in pre-defined periods of 
time and did not recruit random or population representative samples. 
Thus, they cannot be considered as sustained and lasting diagnostic 
interventions, and they could not provide any meaningful epidemio-
logical data. Instead, they could be considered as blind population 
testing, which is unlikely to have any meaningful impact in controlling 
community transmission. 
In the area of epidemiological testing and surveillance, we are aware 
of two published serological studies performed in Greece. In a study 
published in August 2020, 6586 blood samples collected in March and 
April were analyzed for SARS-CoV-2 IgG antibodies using a left-over 
sampling methodology (residual sera from the general population) 
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[87]. Seroprevalence was estimated at 0.02 % and 0.25 % in March and 
April, respectively, with an infection fatality rate of 0.54 %. Based on 
seroprevalence, for every laboratory-confirmed COVID-19 case there 
were approximately 10 additional cases. Although the study was plan-
ned to be repeated at monthly intervals, we were unable to find any 
publication presenting more recent data. Another seroprevalence study 
was performed among students and personnel of the National and 
Kapodistrian University of Athens in June and July, finding a weighted 
overall seroprevalence of 0.93 % [88]. In terms of using diagnostic tests 
(PCR or rapid antigen tests) for epidemiological surveillance purposes, 
to the best of our knowledge, no such studies have been performed in 
Greece. Such studies would be meaningful and important if they 
included population-representative samples and were repeated over 
time in order to timely identify increased transmission in specific areas 
and implement further local measures to contain and mitigate viral 
spread. 
In conclusion, Greece represents a typical case of a country which 
was largely unprepared during the first wave of the pandemic. Addi-
tionally, no priority was given to primary and community healthcare 
reinforcement. The expectation that hospitals would be able to cope 
with the pressure of a highly transmissible virus was unrealistic. In fact, 
during the second pandemic wave, hospitals are under immense pres-
sure and Greece now has one of the highest COVID-19 death rates in 
Europe. Still, even today, no strategy to introduce primary and com-
munity healthcare into a comprehensive plan to mitigate the pandemic 
has been announced. Instead, there are reports that a strategy of 
consecutive horizontal lockdowns, with short periods of partial easing of 
restrictions in-between, is considered. This could potentially have 
catastrophic consequences, not only by failing to prevent as many 
COVID-19-related deaths as possible but also by causing long-lasting 
social, economic and health damage to the population. 
5. Recommendations for primary, community and home care 
reinforcement 
Considering the need to i) implement social distancing measures but 
also avoid strict horizontal lockdowns due to unintended consequences, 
ii) reinforce hospital resources and protect them from patient overload, 
and iii) create a robust find-test-trace-isolate-support system [89], we 
propose the following measures to strengthen the participation of pri-
mary, community and home care in pandemic mitigation, which can be 
implemented in Greece and elsewhere.  
1 Activation, expansion and support of primary health care, both of 
the public sector (health centers, rural and regional medical units 
in Greece) and of the private sector (private-practice physicians 
and family physicians contracted with EOPYY in Greece). 
2 Creation of additional community care teams in every munici-
pality, consisting of community care nurses, health visitors, social 
workers, domestic support staff and psychologists, who will work 
in collaboration with family physicians. These teams will provide 
support for COVID-19 patients who are in quarantine and for non- 
infected, especially the elderly, high-risk and socially deprived, 
individuals who are confined at home in order to avoid exposure 
to SARS-CoV-2 or are adversely affected by the implemented 
restrictions.  
3 Development of a health network engaged in phone and online 
(using eHealth technologies) support for patients with COVID-19, 
with provisions for home visits by healthcare professionals, if 
needed. Such networks should ideally be developed locally in 
each municipality or prefecture, while additional similar net-
works may be created for the management of non-infected but 
high-risk patients who need aggressive primary prevention in-
terventions to protect them from viral exposure and to manage 
comorbidities.  
4 Disengagement of hospitals from the responsibilities of sample 
collection, diagnostic testing, treatment and isolation of people 
infected with SARS-CoV-2 who are ambulatory and do not need 
hospitalized care.  
5 Cooperation between the national public health organizations 
(EODY for Greece) and regional medical associations to adopt 
protocols for the treatment and follow-up of ambulatory COVID- 
19 patients. This will protect hospitals from avoidable and un-
necessary admissions.  
6 Legislation for full compensation of the cost for SARS-CoV-2 
diagnostic testing (rapid antigen and PCR tests) by social insur-
ance or by the government (EOPYY for Greece) even if prescribed 
by private-practice physicians and performed in private labora-
tories. This will massively increase testing capacity, will ensure 
timely availability and accessibility to diagnostic tests for every 
person with an indication to be tested and will relieve hospitals 
from the responsibility to perform diagnostic tests.  
7 Compensation of private-practice physicians for monitoring and 
treating patients with COVID-19, including home and distant 
(phone or online) care. This will increase healthcare professional 
resources by recruiting a large number of physicians who do not 
currently participate in pandemic mitigation in countries such as 
Greece.  
8 Creation of a network of laboratories and contact tracing teams at 
regional or prefectural level. This will increase the speed of 
identification, diagnosis, contact tracing and isolation of infected 
people.  
9 Implementation of frequent and repeated testing for the nursing 
home population and staff using rapid antigen tests or PCR tests. 
These are usually crowded facilities which favor viral trans-
mission and exposure to high viral load, while people who live in 
these facilities are at high risk for severe COVID-19. Similar in-
terventions should be organized for other facilities caring for 
high-risk individuals.  
10 Provision for accommodation facilities for COVID-19 patients 
who need to be quarantined but do not have a place to isolate (e. 
g., homeless people, COVID-19 patients in nursing homes who 
need to be transferred in order to prevent transmission to others, 
refugees, COVID-19 patients who request accommodation 
because there have vulnerable family members who cannot be 
protected from viral exposure). Authorities could lease hotels or 
other buildings, and provide essential primary care support for 
these ambulatory patients.  
11 Development of a plan for repeated, random or population- 
representative testing in each prefecture, using rapid antigen 
and antibody tests. It is essential to systematically monitor the 
epidemiological burden and population immunity so that timely 
and targeted interventions can be made at a local level.  
12 Preparation of a comprehensive plan for the gradual lifting of the 
strict, horizontal lockdown as early as possible, which will 
include more selective social distancing measures focused on 
protecting vulnerable population subgroups, and additional re-
strictions implemented on a local level depending on the 
continuously-monitored epidemiological profile. 
The above measures should be combined with other interventions 
such as social distancing measures in schools and public transport to 
prevent cluster infections [90]. Public education programs are also 
needed, which should provide information about COVID-19 related is-
sues such as protective measures, but also emphasize on lifestyle and 
dietary modifications which could contribute to immune system health 
[91]. We cannot emphasize enough the need for schools, particularly 
primary schools, to remain open, since children have a very low risk for 
severe COVID-19 while, on the contrary, school closure can cause 
serious harms. Finally, it is important that all available epidemiological 
evidence should be accessible to the scientific community in full 
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transparency so that extensive analysis and a critical assessment of 
current and future decisions can be made. These principles and measures 
can be followed in many countries, adjusted according to local needs 
and unique characteristics of their healthcare system. 
6. Conclusion 
In anticipation of safe and effective vaccines, and given the uncer-
tainty of both the magnitude and duration of their effectiveness as well 
as the expected delays in vaccinating large parts of the population, we 
need to become more creative, practical and effective. By carefully 
studying the unique epidemiological and clinical characteristic of the 
virus and the resulting pandemic, and by learning from past mistakes 
and from the experience of other countries, we can develop more 
effective strategies that will result in sustained suppression of commu-
nity transmission. Strict, horizontal lockdowns cannot be used as the 
core of a long-term strategy for pandemic mitigation because of 
important adverse social, economic and health effects that have yet to be 
fully elucidated. A holistic approach is required, by recognizing the 
irreplaceable role of primary, community and home care, which should 
be at the forefront in managing the COVID-19 pandemic and the asso-
ciated adverse effects for the population. 
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[13] B. Ibáñez, Myocardial infarction in times of COVID-19, Rev Esp. Cardiol. (Engl Ed) 
(October) (2020) 30, https://doi.org/10.1016/j.rec.2020.09.023. S1885-5857(20) 
30461-30468. 
[14] G. De Luca, M. Verdoia, M. Cercek, L.O. Jensen, M. Vavlukis, L. Calmac, et al., 
Impact of COVID-19 pandemic on mechanical reperfusion for patients with STEMI, 
J. Am. Coll. Cardiol. 76 (November (20)) (2020) 2321–2330, https://doi.org/ 
10.1016/j.jacc.2020.09.546. 
[15] J. Wu, M.A. Mamas, M.O. Mohamed, C.S. Kwok, C. Roebuck, B. Humberstone, 
T. Denwood, T. Luescher, M.A. de Belder, J.E. Deanfield, C.P. Gale, Place and 
causes of acute cardiovascular mortality during the COVID-19 pandemic, Heart 
(September) (2020) 28, https://doi.org/10.1136/heartjnl-2020-317912, heartjnl- 
2020-317912. 
[16] A. Bilinski, E.J. Emanuel, COVID-19 and excess all-cause mortality in the US and 18 
comparison countries, JAMA 12 (October) (2020), e2020717, https://doi.org/ 
10.1001/jama.2020.20717. 
[17] K. Docherty, J. Butt, R. de Boer, P. Dewan, L. Koeber, A. Maggioni, J. McMurray, 
S. Solomon, P.S. Jhund, Excess deaths during the Covid-19 pandemic: an 
international comparison, medRxiv (2020), https://doi.org/10.1101/ 
2020.04.21.20073114, 04.21.20073114. 
[18] Breast Cancer Now, Almost One Million Women in UK Miss Vital Breast Screening 
Due to COVID-19, 2020. September 30. Available at: https://breastcancernow.org/ 
about-us/media/press-releases/almost-one-million-women-in-uk-miss-vital-breast- 
screening-due-covid-19. Accessed on 06 November 2020. 
[19] L. Hawryluck, W.L. Gold, S. Robinson, S. Pogorski, S. Galea, R. Styra, SARS control 
and psychological effects of quarantine, Toronto, Canada, Emerg Infect Dis. 10 
(July(7)) (2004) 1206–1212, https://doi.org/10.3201/eid1007.030703. 
[20] E.R. Walker, R.E. McGee, B.G. Druss, Mortality in mental disorders and global 
disease burden implications: a systematic review and meta-analysis, JAMA 
Psychiatry 72 (April(4)) (2015) 334–341, https://doi.org/10.1001/ 
jamapsychiatry.2014.2502. Erratum in: JAMA Psychiatry. 2015 Jul;72(7):736. 
Erratum in: JAMA Psychiatry. 2015 Dec;72(12):1259. 
[21] D.A. Moser, J. Glaus, S. Frangou, D.S. Schechter, Years of life lost due to the 
psychosocial consequences of COVID-19 mitigation strategies based on Swiss data, 
Eur. Psychiatry 63 (May (1)) (2020) e58, https://doi.org/10.1192/j. 
eurpsy.2020.56. 
K. Farsalinos et al.                                                                                                                                                                                                                              
Toxicology Reports 8 (2021) 1–9
8
[22] K. Magklara, H. Lazaratou, B. Barbouni, K. Poulas, K. Farsalinos, Coronavirus 
Greece Research Group. Impact of COVID-19 pandemic and lockdown measures on 
mental health of children and adolescents in Greece, medRxiv (2020), https://doi. 
org/10.1101/2020.10.18.20214643, 10.18.20214643. 
[23] S. Singh, D. Roy, K. Sinha, S. Parveen, G. Sharma, G. Joshi, Impact of COVID-19 
and lockdown on mental health of children and adolescents: a narrative review 
with recommendations, Psychiatry Res. 24 (August) (2020) 293, https://doi.org/ 
10.1016/j.psychres.2020.113429, 113429. 
[24] J. Marsden, S. Darke, W. Hall, M. Hickman, J. Holmes, K. Humphreys, J. Neale, 
J. Tucker, R. West, Mitigating and learning from the impact of COVID-19 infection 
on addictive disorders, Addiction 115 (June(6)) (2020) 1007–1010, https://doi. 
org/10.1111/add.15080. 
[25] F. Pascual Pastor, M. Isorna Folgar, N. Carvalho, F. Carvalho, F. Arias Horcajadas, 
Therapeutic Cannabis and COVID-19: between opportunism and infoxication, 
Adicciones 32 (July (3)) (2020) 167–172, https://doi.org/10.20882/ 
adicciones.1603. English, Spanish. 
[26] M. Nicola, Z. Alsafi, C. Sohrabi, A. Kerwan, A. Al-Jabir, C. Iosifidis, M. Agha, 
R. Agha, The socio-economic implications of the coronavirus pandemic (COVID- 
19): a review, Int. J. Surg. 78 (June) (2020) 185–193, https://doi.org/10.1016/j. 
ijsu.2020.04.018. 
[27] S. Sardar, I. Abdul-Khaliq, A. Ingar, H. Amaidia, N. Mansour, ’COVID-19 lockdown: 
a protective measure or exacerbator of health inequalities? A comparison between 
the United Kingdom and India.’ a commentary on “the socio-economic 
implications of the coronavirus and COVID-19 pandemic: a review”, Int. J. Surg. 29 
(September 83) (2020) 189–191, https://doi.org/10.1016/j.ijsu.2020.09.044. 
[28] A. Gagnon, M.S. Miller, S.A. Hallman, R. Bourbeau, D.A. Herring, D.J. Earn, 
J. Madrenas, Age-specific mortality during the 1918 influenza pandemic: 
unravelling the mystery of high young adult mortality, PLoS One 8 (August (8)) 
(2013), e69586, https://doi.org/10.1371/journal.pone.0069586. 
[29] A.O. Docea, A. Tsatsakis, D. Albulescu, O. Cristea, O. Zlatian, M. Vinceti, S. 
A. Moschos, D. Tsoukalas, M. Goumenou, N. Drakoulis, J.M. Dumanov, V. 
A. Tutelyan, G.G. Onischenko, M. Aschner, D.A. Spandidos, D. Calina, A new threat 
from an old enemy: Re‑emergence of coronavirus (Review), Int. J. Mol. Med. 45 
(June(6)) (2020) 1631–1643, https://doi.org/10.3892/ijmm.2020.4555. 
[30] A. Tsatsakis, D. Calina, L. Falzone, D. Petrakis, R. Mitrut, V. Siokas, M. Pennisi, 
G. Lanza, M. Libra, S.G. Doukas, P.G. Doukas, L. Kavali, A. Bukhari, C. Gadiparthi, 
D.P. Vageli, D.P. Kofteridis, D.A. Spandidos, M.M.B. Paoliello, M. Aschner, A. 
O. Docea, SARS-CoV-2 pathophysiology and its clinical implications: an integrative 
overview of the pharmacotherapeutic management of COVID-19, Food Chem. 
Toxicol. 146 (September) (2020) 111769, https://doi.org/10.1016/j. 
fct.2020.111769. 
[31] G.T. Gerotziafas, T.N. Sergentanis, G. Voiriot, L. Lassel, C. Papageorgiou, 
A. Elabbadi, M. Turpin, P. Vandreden, L. Papageorgiou, T. Psaltopoulou, E. Terpos, 
M.A. Dimopoulos, A. Parrot, J. Cadranel, G. Pialoux, M. Fartoukh, I. Elalamy, 
Derivation and validation of a predictive score for disease worsening in patients 
with COVID-19, Thromb. Haemost. (September) (2020) 22, https://doi.org/ 
10.1055/s-0040-1716544. 
[32] B. Benjamin Wachtler, N. Michalski, E. Nowossadeck, M. Diercke, M. Wahrendorf, 
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